Non-medics may care not to read this!
Dr Crippen has THIS post today about the lack of availability of Tarceva (erlotinib), a drug about which he has strong views and has previously posted. I think it may be helpful to consider the case of this drug in a little more detail. Tarceva is a drug which is licensed for the treatment of lung cancer after previous chemotherapy. It is no available on the NHS as it is deemed by NICE not to be cost-effective (though interestingly it is cost-effective in scotland-work that one out if you can!)
There are 2 other drugs licensed in this situation, namely docetaxel and pemetrexed. Only docetaxel is available in the NHS. The following are 3 graphs showing the survival figures for 1) tarceva vs placebo, 2) docetaxel vs supportive care and 3) docetaxel vs pemetrexed
1)

2)

3)

They show (to me, anyway) that both docetaxel and tarceva give a survival advantage over supportive care alone, amounting to an approximately 10% absolute survival advantage at 1 year. The third graph shows that pemetrexed is as effective as docetaxel.
The costs of these drugs (approximately) are as follows:
Tarceva £1,800 per month (average course will be around 3 months, may go up to 18 months)
Docetaxel £6600 per course
Pemetrexed £8000 per course
These drugs have different side effects, different risks, one may be more suitable for one patient than another. I believe they all have a role, and in the private sector I am able to discuss with patients the pros and cons of each and come to a decision as to which is better for an individual patient. Why am I not allowed to do the same in the NHS, where the choice is docetaxel or nothing? Just because it is the cheapest does not make it the best choice. Indeed for a patient who is likely to have side effects from docetaxel, tarceva may be more cost-effective. The only people who will be on the treatment fo more than 6 months will be those who are benefiting, and in those patients the drug is cost-effective. The people in the best position to make these decisions are the oncologist and the patient, NOT the DoH. If they had their way, oncology could be practised by automatons.
Now, that said there has to be rationing in the NHS. There will be drugs and treatments that we cannot afford. I feel, however that if these treatments are available in every other developed country but not the UK, then we have set the cost limit too low, and this is reflected in the fact that our cancer outcomes are amongst the worst in the developed world. It might be that we decide that this is acceptable and we will not devote resources to treating cancer as it is not cost-effective. If so, I will look for a new job.